Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary Cain

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Toxicology and Applied Pharmacology|July 15, 2023
Smarca2 genetic ablation is phenotypically benign in a safety assessment of tamoxifen-inducible conditional knockout ratsJonathan Maher, Nicola Stagg, Gary Cain, et al.
Mabs|June 19, 2013
Generation and characterization of a unique reagent that recognizes a panel of recombinant human monoclonal antibody therapeutics in the presence of endogenous human IgGXiangdan Wang, Valerie Quarmby, Carl Ng, et al.
Toxicologic Pathology|March 20, 2025
Scientific and Regulatory Policy Committee Points to Consider* for Determining and Reporting Cause of Death/Moribundity in Non-Rodent Species in Toxicity StudiesKaryn Colman, Kathleen A Funk, Michael Boyle, et al.
Plos One|June 8, 2018
Interrogation of transcriptomic changes associated with drug-induced hepatic sinusoidal dilatation in colorectal cancerMonika A Jarzabek, William R Proctor, Jennifer Vogt, et al.
Molecular Cancer Therapeutics|July 23, 2013
Combination drug scheduling defines a "window of opportunity" for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900Elizabeth Blackwood, Jennifer Epler, Ivana Yen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2015
Balancing Efficacy and Safety of an Anti-DLL4 Antibody through Pharmacokinetic ModulationJessica A Couch, Gu Zhang, Joseph C Beyer, et al.
Molecular Cancer Therapeutics|January 7, 2012
Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer modelCinthia V Pastuskovas, Eduardo E Mundo, Simon P Williams, et al.
Journal of Medicinal Chemistry|May 12, 2016
Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic WindowJoachim Rudolph, Lesley J Murray, Chudi O Ndubaku, et al.
Science Translational Medicine|November 23, 2018
Lung-restricted inhibition of Janus kinase 1 is effective in rodent models of asthmaHart S Dengler, Xiumin Wu, Ivan Peng, et al.
Journal of Medicinal Chemistry|March 3, 2024
Discovery of TRPA1 Antagonist <b>GDC-6599</b>: Derisking Preclinical Toxicity and Aldehyde Oxidase Metabolism with a Potential First-in-Class Therapy for Respiratory DiseaseJack A Terrett, Justin Q Ly, Paula Katavolos, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Toxicology and Applied Pharmacology|July 15, 2023
Smarca2 genetic ablation is phenotypically benign in a safety assessment of tamoxifen-inducible conditional knockout ratsJonathan Maher, Nicola Stagg, Gary Cain, et al.
Mabs|June 19, 2013
Generation and characterization of a unique reagent that recognizes a panel of recombinant human monoclonal antibody therapeutics in the presence of endogenous human IgGXiangdan Wang, Valerie Quarmby, Carl Ng, et al.
Toxicologic Pathology|March 20, 2025
Scientific and Regulatory Policy Committee Points to Consider* for Determining and Reporting Cause of Death/Moribundity in Non-Rodent Species in Toxicity StudiesKaryn Colman, Kathleen A Funk, Michael Boyle, et al.
Plos One|June 8, 2018
Interrogation of transcriptomic changes associated with drug-induced hepatic sinusoidal dilatation in colorectal cancerMonika A Jarzabek, William R Proctor, Jennifer Vogt, et al.
Molecular Cancer Therapeutics|July 23, 2013
Combination drug scheduling defines a "window of opportunity" for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900Elizabeth Blackwood, Jennifer Epler, Ivana Yen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2015
Balancing Efficacy and Safety of an Anti-DLL4 Antibody through Pharmacokinetic ModulationJessica A Couch, Gu Zhang, Joseph C Beyer, et al.
Molecular Cancer Therapeutics|January 7, 2012
Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer modelCinthia V Pastuskovas, Eduardo E Mundo, Simon P Williams, et al.
Journal of Medicinal Chemistry|May 12, 2016
Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic WindowJoachim Rudolph, Lesley J Murray, Chudi O Ndubaku, et al.
Science Translational Medicine|November 23, 2018
Lung-restricted inhibition of Janus kinase 1 is effective in rodent models of asthmaHart S Dengler, Xiumin Wu, Ivan Peng, et al.
Journal of Medicinal Chemistry|March 3, 2024
Discovery of TRPA1 Antagonist <b>GDC-6599</b>: Derisking Preclinical Toxicity and Aldehyde Oxidase Metabolism with a Potential First-in-Class Therapy for Respiratory DiseaseJack A Terrett, Justin Q Ly, Paula Katavolos, et al.
Pageof 2